----item----
version: 1
id: {65EB99B6-7C29-4844-B50B-CB6755EE5BB4}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/18/PharmAsia News Business Bulletin
parent: {699941D8-9EE7-4139-9D7E-1D993A9625CE}
name: PharmAsia News Business Bulletin
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 43d04fea-ce66-454e-8821-a5514b603af1

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 3235

<p>A new regular roundup of commercial stories appearing in Scrip&rsquo;s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p><p><p>Full stories can be accessed by clicking on the story title (subscription required).</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/16/roche-sees-oncology-access-programs-key-to-growth" target="_new">Roche Sees Oncology Access Programs Key To Growth</a></p><p>Against a backdrop of increasing payer scrutiny over the high price tags of new cancer treatments, Roche is looking at two main strategies to ensure access to its therapies in the sector, covering both developed countries and emerging markets.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/16/abbott-india-confident-despite-phensedyl-problems" target="_new">Abbott India Confident Despite Phensedyl Problems</a></p><p>Abbott India, part of the US-based global healthcare company, says it is confident about the safety of its popular cough syrup Phensedyl, after it was reported that a government laboratory test found a sample bottle allegedly contained an excessive amount of codeine.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/17/japanese-pharma-steps-up-neglected-disease-activity" target="_new">Japanese Pharma Steps Up Neglected Disease Activity</a></p><p>Two major Japanese pharma firms have announced new initiatives to boost research into neglected tropical diseases, in line with a steady increase in research activity in this area by companies in the country.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/15/zenyaku-ends-japan-alliance-with-anthera" target="_new">Zenyaku Ends Japan Alliance With Anthera</a></p><p>Anthera's development partner in Japan for autoimmune disorder drug blisibimod has served a termination notice for the late 2014 deal, but the US firm says the impact could in fact be positive.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/14/actos-settlement-in-sight-as-first-threshold-crossed" target="_new">Actos Settlement In Sight As First Threshold Crossed</a></p><p>More than 95% of eligible US claimants have decided to take up Takeda's offer of no fault financial resolution of product liability claims against its former blockbuster Actos, triggering the first steps towards a settlement.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/14/korea-oks-gileads-sovaldi-all-eyes-on-pricing" target="_new">Korea OKs Gilead's Sovaldi, All Eyes On Pricing</a></p><p>South Korea has granted approval to Gilead's Sovaldi as a therapy for adults with genotype 1, 2, 3 or 4 chronic hepatitis C in combination with other therapies. All eyes are now on whether all four genotypes will be covered by the national health insurance scheme and at what price the drug will be sold in the country, as the company negotiates for reimbursement with the government over the next few months.</p><p><p><a href="http://www.pharmasianews.com" target="_new">www.pharmasianews.com</a></p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 235

<p>A new regular roundup of commercial stories appearing in Scrip&rsquo;s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150918T160001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150918T160001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150918T160001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029809
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{DB39CCA6-EB88-422C-8247-AB4AD01491E2}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360459
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042451Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

43d04fea-ce66-454e-8821-a5514b603af1
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042451Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
